Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6721-6726

  Zekri, Abd El Rahman Nabawy ^a   Nassar, Auhood Abdel Monem ^a   El Rouby, Mahmoud Nour El Din ^a   Shousha, Hend Ibrahim ^b   Barakat, Ahmed Barakat ^c   El Desouky, Eman Desouky ^a   Zayed, Naglaa Ali ^b   Ahmed, Ola Sayed ^a   Youssef, Amira Salah El Din ^a   Kaseb, Ahmed Omar ^d   El Aziz, Ashraf Omar Abd ^b   Bahnassy, Abeer Ahmed ^a  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Ain Shams University   (Egypt)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cirrhosis; HCV; Hepatocellular carcinoma; Progression; Tumor suppressor gene methylation

Indexed keywords

EID: 84892460417     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6721     Document Type: Article

References (26)

1. Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91.
2. Anzola M, Cuevas N, López-Martínez M, et al (2004). P14ARF gene alterations in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 16, 19-26.
3. Chang H, Yi B, Li L, et al (2008). Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol, 85, 96-100.
4. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10. Lyon, France: International Agency for Research on Cancer.
5. Fukai K, Yokosuka O, Imazeki F, et al (2005). Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma. Liver Int, 25, 1209-16.
6. Herbst A, Rahmig K, Stieber P, et al (2011). Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol, 106, 1110-8.
7. Iakova P, Timchenko L, Timchenko NA (2011). Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol, 21, 28-34.
8. Iwata N, Yamamoto H, Sasaki S, et al (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene, 19, 5298-302.
9. Iyer P, Zekri AR, Hung CW, et al (2009). Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol, 88, 107-11.
10. Jung N, Won JK, Kim BH, et al (2012). Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma. J Korean Med Sci, 27, 594-604.
11. Lavanchy D (2011). Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect, 17, 107-15.
12. Lee S, Lee HJ, Kim JH, et al (2003). Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol, 163, 1371-8.
13. Liu WJ, Wang L, Wang JP, et al (2006). Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma. Ai Zheng, 25, 696-700.
14. Matsukura S, Soejima H, Nakagawachi T, et al (2003). CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer, 88, 521-9.
15. McGivern DR, Lemon SM (2011). Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene, 30, 1969-83.
16. Nomoto S, Kinoshita T, Kato K, et al (2007). Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer, 97, 1260-5.
17. Parkin DM, Bray F, Ferlay J (2005). Global cancer statistics, 2002. CA Cancer J Clin, 25, 74-108.
18. Peng CY, Chen TC, Hung SP, et al (2002). Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res, 22, 1265-71.
19. Salhab M, Canelo R (2011). An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Can Res Ther, 7, 463-75.
20. Schütte K, Bornschein J, Malfertheiner P (2009). Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis, 27, 80-92.
21. Shih YL, Shyu RY, Hsieh CB, et al (2006). Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer, 107, 579-90.
22. Whittaker S, Marais R, Zhu AX (2010). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29, 4989-5005.
23. Yamashita T, Honda M, Kaneko S (2011). Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J. Gastroenterol. Hepatol, 26, 960-4.
24. Yang B, Guo M, Herman JG, Clark DP (2003). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 163, 1101-7.
25. Zhang YJ, Wu HC, Shen J, et al (2007). Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res, 13, 2378-84.
26. Zhao ZH, Geng XP, Zhu LX, Li HM, Liew CT (2005). Hypermethylation of Ras association domain family protein 1A, hypermethylated in cancer 1 and p73 genes in hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi, 43, 1528-32.